AU649217B2 - Method for site-specifically incorporating unnatural amino acids into proteins - Google Patents

Method for site-specifically incorporating unnatural amino acids into proteins

Info

Publication number
AU649217B2
AU649217B2 AU47412/90A AU4741290A AU649217B2 AU 649217 B2 AU649217 B2 AU 649217B2 AU 47412/90 A AU47412/90 A AU 47412/90A AU 4741290 A AU4741290 A AU 4741290A AU 649217 B2 AU649217 B2 AU 649217B2
Authority
AU
Australia
Prior art keywords
trna
protein
amino acid
aminoacyl
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU47412/90A
Other languages
English (en)
Other versions
AU4741290A (en
Inventor
Peter Schultz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of AU4741290A publication Critical patent/AU4741290A/en
Application granted granted Critical
Publication of AU649217B2 publication Critical patent/AU649217B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/86—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides, e.g. penicillinase (3.5.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU47412/90A 1988-11-18 1989-11-15 Method for site-specifically incorporating unnatural amino acids into proteins Ceased AU649217B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US27345588A 1988-11-18 1988-11-18
US273455 1988-11-18
US33760189A 1989-04-13 1989-04-13
US337601 1989-04-13
PCT/US1989/005256 WO1990005785A1 (fr) 1988-11-18 1989-11-15 Procede d'incorporation sur un site specifique, d'aminoacides non naturels dans des proteines

Publications (2)

Publication Number Publication Date
AU4741290A AU4741290A (en) 1990-06-12
AU649217B2 true AU649217B2 (en) 1994-05-19

Family

ID=26956206

Family Applications (1)

Application Number Title Priority Date Filing Date
AU47412/90A Ceased AU649217B2 (en) 1988-11-18 1989-11-15 Method for site-specifically incorporating unnatural amino acids into proteins

Country Status (5)

Country Link
EP (1) EP0446299A4 (fr)
JP (1) JPH04504651A (fr)
KR (1) KR900702044A (fr)
AU (1) AU649217B2 (fr)
WO (1) WO1990005785A1 (fr)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005749A1 (fr) * 1988-11-18 1990-05-31 The Regents Of The University Of California Polypeptides conjugues, leurs procedes de preparation et d'utilisation
US6943034B1 (en) 1991-11-22 2005-09-13 Affymetrix, Inc. Combinatorial strategies for polymer synthesis
DE69233331T3 (de) * 1991-11-22 2007-08-30 Affymetrix, Inc., Santa Clara Kombinatorische Strategien zur Polymersynthese
US5922545A (en) * 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US6358689B1 (en) 1994-05-11 2002-03-19 Boston University Detection of markers in nascent proteins
US5986076A (en) * 1994-05-11 1999-11-16 Trustees Of Boston University Photocleavable agents and conjugates for the detection and isolation of biomolecules
US5643722A (en) 1994-05-11 1997-07-01 Trustees Of Boston University Methods for the detection and isolation of proteins
US6210941B1 (en) 1997-06-27 2001-04-03 The Trustees Of Boston University Methods for the detection and isolation of proteins
US6239273B1 (en) 1995-02-27 2001-05-29 Affymetrix, Inc. Printing molecular library arrays
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
DE69720041T2 (de) * 1996-11-14 2004-01-08 Affymetrix, Inc., Santa Clara Chemische amplifizierung zur synthese von musterordnungen
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6653126B1 (en) 1999-06-04 2003-11-25 Massachusetts Insititute Of Technology Compositions and methods for the screening of compounds to enhance or reduce apoptosis
US6306628B1 (en) 1999-08-25 2001-10-23 Ambergen, Incorporated Methods for the detection, analysis and isolation of Nascent proteins
WO2001068835A2 (fr) * 2000-03-13 2001-09-20 Aptagen Technique de modification d'un acide nucleique
US7252932B1 (en) 2000-08-23 2007-08-07 Ambergen, Inc. Methods for the detection, analysis and isolation of nascent proteins
KR100401296B1 (ko) * 2000-12-27 2003-10-11 드림바이오젠 주식회사 수식물질에 의해 수식된 단백질 변이체 및 이것의 제조방법
JP4061043B2 (ja) 2000-12-28 2008-03-12 株式会社ポストゲノム研究所 ｉｎｖｉｔｒｏ転写／翻訳系によるペプチド等の製造方法
WO2002059601A1 (fr) * 2001-01-23 2002-08-01 President And Fellows Of Harvard College Reseaux de proteines a acide nucleique programmable
EP1401850A1 (fr) 2001-06-20 2004-03-31 Nuevolution A/S Derives nucleosidiques pour elaboration de bibliotheque combinatoire
GB0115841D0 (en) 2001-06-28 2001-08-22 Medical Res Council Ligand
EP1440083B1 (fr) 2001-10-25 2013-01-02 Medical Research Council Molecules
AU2002349296A1 (en) * 2001-11-30 2003-06-10 Novozymes A/S Method for generating a site-specific library of variants
US7288372B2 (en) 2002-01-17 2007-10-30 Ambergen, Inc. Methods for the preparation of chemically misaminoacylated tRNA via protective groups
CN101006177B (zh) 2002-03-15 2011-10-12 纽韦卢森公司 改善的用于合成模制分子的方法
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US10730906B2 (en) 2002-08-01 2020-08-04 Nuevolutions A/S Multi-step synthesis of templated molecules
ES2640279T3 (es) 2002-10-30 2017-11-02 Nuevolution A/S Procedimiento para la síntesis de un complejo bifuncional
US9121110B2 (en) 2002-12-19 2015-09-01 Nuevolution A/S Quasirandom structure and function guided synthesis methods
WO2004074429A2 (fr) 2003-02-21 2004-09-02 Nuevolution A/S Procede de production d'une banque de deuxieme generation
DK2236606T3 (da) 2003-03-20 2014-02-10 Nuevolution As Kodning af små molekyler ved ligering
DE10336705A1 (de) * 2003-08-06 2005-03-10 Rina Netzwerk Rna Technologien Verfahren zur Herstellung eines Lysats zur zellfreien Proteinbiosynthese
DE602004023960D1 (de) 2003-09-18 2009-12-17 Nuevolution As Methode zur Gewinnung struktureller Informationen kodierter Moleküle und zur Selektion von Verbindungen
JP2007519422A (ja) 2004-02-02 2007-07-19 アンブレツクス・インコーポレイテツド 修飾されたヒト四螺旋バンドルポリペプチド及びそれらの使用
DK1730277T3 (da) 2004-03-22 2010-03-01 Nuevolution As Kodning ved ligering under anvendelse af byggebloksoligonukleotider
MXPA06014684A (es) 2004-06-18 2007-02-12 Ambrx Inc Novedosos polipeptidos de enlace antigeno y sus usos.
CN101724071A (zh) 2004-10-08 2010-06-09 杜门蒂斯有限公司 抗肿瘤坏死因子受体1的单域抗体及其使用方法
BRPI0519430A2 (pt) 2004-12-22 2009-02-10 Ambrx Inc hormânio do crescimento humano modificado
ATE541934T1 (de) 2004-12-22 2012-02-15 Ambrx Inc Zusammensetzungen von aminoacyl-trna-synthetase und verwendungen davon
SG161210A1 (en) 2004-12-22 2010-05-27 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
WO2006069246A2 (fr) 2004-12-22 2006-06-29 Ambrx, Inc. Compositions contenant des acides amines non naturels et des polypeptides, procedes impliquant ces acides amines non naturels et polypeptides, et utilisations desdits acides amines non naturels et polypeptides
AU2005322019B2 (en) 2004-12-22 2010-08-26 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid
EP1863531A1 (fr) 2005-03-19 2007-12-12 Medical Research Council Ameliorations dans ou concernant le traitement et la prevention d'infections virales
KR20080026135A (ko) 2005-06-03 2008-03-24 암브룩스, 인코포레이티드 개선된 인간 인터페론 분자 및 이의 용도
PT1954710E (pt) 2005-11-08 2011-06-07 Ambrx Inc Aceleradores para a modificação de aminoácidos nãonaturais e polipeptídeos de aminoácidos não-naturais
EP2339014B1 (fr) 2005-11-16 2015-05-27 Ambrx, Inc. Procédés et compositions comprenant des acides aminés non naturels
SI2341140T1 (sl) 2005-12-01 2017-12-29 Nuevolution A/S Postopki encimskega kodiranja za učinkovito sintezo velikih knjižnic
KR101423898B1 (ko) 2005-12-14 2014-07-28 암브룩스, 인코포레이티드 비-천연 아미노산 및 폴리펩티드를 함유하는 조성물, 비-천연 아미노산 및 폴리펩티드를 포함하는 방법, 및 비-천연 아미노산 및 폴리펩티드의 용도
US8178316B2 (en) 2006-06-29 2012-05-15 President And Fellows Of Harvard College Evaluating proteins
US8420792B2 (en) 2006-09-08 2013-04-16 Ambrx, Inc. Suppressor tRNA transcription in vertebrate cells
NZ574721A (en) 2006-09-08 2012-02-24 Ambrx Inc Hybrid suppressor trna for vertebrate cells
EP2069396B1 (fr) 2006-09-08 2015-10-21 Ambrx, Inc. Polypeptide plasmatique humain modifie ou squelettes de fc et leurs utilisations
CA2669084A1 (fr) 2006-11-10 2008-05-29 Massachusetts Institute Of Technology Modulateurs de pak
BRPI0809583B1 (pt) 2007-03-30 2022-02-22 Ambrx, Inc Polipeptídeo fgf-21 modificado, composição compreendendo o mesmo, método para produzir o referido polipetídeo fgf-21 e célula compreendendo um polinucleotídeo
CA2685596A1 (fr) 2007-05-02 2008-11-13 Ambrx, Inc. Polypeptides d'interferon beta modifies et leurs utilisations
NZ603812A (en) 2007-11-20 2014-06-27 Ambrx Inc Modified insulin polypeptides and their uses
SG188143A1 (en) 2008-02-08 2013-03-28 Ambrx Inc Modified leptin polypeptides and their uses
EP2096174A1 (fr) 2008-02-28 2009-09-02 Centro De Investigación Cooperativa En Biociencias CiC bioGune Polypeptides se liant à l'ubiquitine
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
NZ591235A (en) 2008-07-23 2012-07-27 Ambrx Inc Modified bovine g-csf polypeptides comprising non natural amino acid and their uses treating infections such as mastitis
TR201802361T4 (tr) 2008-09-26 2018-03-21 Ambrx Inc Doğal olmayan amino asit replikasyonuna bağımlı mikroorganizmalar ve aşılar.
PL2342223T3 (pl) 2008-09-26 2017-09-29 Ambrx, Inc. Zmodyfikowane polipeptydy zwierzęcej erytropoetyny i ich zastosowania
EP2501414B1 (fr) 2009-11-17 2018-01-10 The Trustees Of The University Of Pennsylvania Dégron smndelta7 : nouvelles compositions et procédés d'utilisation
NZ600361A (en) 2009-12-21 2014-06-27 Ambrx Inc Modified bovine somatotropin polypeptides and their uses
CN104017063A (zh) 2009-12-21 2014-09-03 Ambrx公司 经过修饰的猪促生长素多肽和其用途
LT2558577T (lt) 2010-04-16 2019-03-12 Nuevolution A/S Bifunkciniai kompleksai ir tokių kompleksų gamybos ir naudojimo būdai
MY162837A (en) 2010-08-17 2017-07-31 Ambrx Inc Modified relaxin polypeptides and their uses
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
ES2525573T3 (es) 2011-05-24 2014-12-26 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Trampas de SUMO de alta afinidad
KR101646728B1 (ko) * 2014-08-27 2016-08-09 동국대학교 산학협력단 디제너러시 리프로그래밍을 통한 비천연 단백질 합성 방법
UY36370A (es) 2014-10-24 2016-04-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Polipéptidos fgf-21 modificados y sus usos
MA41629A (fr) 2015-03-04 2018-01-09 Center For Human Reproduction Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
ES2963839T3 (es) 2017-02-08 2024-04-02 Bristol Myers Squibb Co Polipéptidos de relaxina modificados que comprenden un potenciador farmacocinético y usos de los mismos
CN112119092A (zh) 2018-02-12 2020-12-22 无糖尿病公司 改进的拮抗性抗人cd40单克隆抗体
US20210387020A1 (en) 2018-10-19 2021-12-16 University Of Rochester Immune modulators in combination with radiation treatment for advanced pancreatic cancer
WO2020102454A1 (fr) 2018-11-13 2020-05-22 Regents Of The University Of Minnesota Peptides ciblant le cd40 et leurs utilisations
WO2020140007A1 (fr) 2018-12-28 2020-07-02 University Of Rochester Thérapie génique pour mutations dominantes best1
EP3917571A4 (fr) 2019-01-31 2022-10-12 Agency For Science, Technology And Research Inhibiteur cnx/erp57 destiné à être utilisé dans le traitement ou la prévention du cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4568640A (en) * 1981-05-11 1986-02-04 Harvey Rubin Method of inserting amino acid analogs into proteins
US4687737A (en) * 1982-11-12 1987-08-18 Massachusetts Institute Of Technology Mammalian suppressor genes

Also Published As

Publication number Publication date
KR900702044A (ko) 1990-12-05
JPH04504651A (ja) 1992-08-20
EP0446299A1 (fr) 1991-09-18
EP0446299A4 (en) 1992-05-13
WO1990005785A1 (fr) 1990-05-31
AU4741290A (en) 1990-06-12

Similar Documents

Publication Publication Date Title
AU649217B2 (en) Method for site-specifically incorporating unnatural amino acids into proteins
Noren et al. A general method for site-specific incorporation of unnatural amino acids into proteins
Ma et al. In vitro protein engineering using synthetic tRNAAla with different anticodons
US8980581B2 (en) Site-specific incorporation of amino acids into molecules
EP2380982B1 (fr) Composants de translation orthogonale pour une incorporation in vivo d'acides aminés non naturels
EP1991680B1 (fr) Système d'expression de composantes de traduction orthogonale dans des cellules hôtes d'eubactéries
EP2052083B1 (fr) Expression génétiquement programmée de protéines sulfatées sélectivement dans des eubactéries
US20130210073A1 (en) Methods of incorporating amino acid analogs into proteins
US20040259081A1 (en) Method for protein expression starting from stabilized linear short DNA in cell-free in vitro transcription/translation systems with exonuclease-containing lysates or in a cellular system containing exonucleases
CA2232234A1 (fr) Procede de production de plasmides de recombinaison
US20220243244A1 (en) Compositions and methods for in vivo synthesis of unnatural polypeptides
US20220228148A1 (en) Eukaryotic semi-synthetic organisms
EP1356036B1 (fr) Methode et compositions de synthese de peptides, de proteines et de peptidomimetiques
US20160115487A1 (en) Cell-free synthetic incorporation of non-natural amino acids into proteins
Liu et al. Recognition of the universally conserved 3'-CCA end of tRNA by elongation factor EF-Tu.
Leon et al. tRNA recognition site of Escherichia coli methionyl-tRNA synthetase
Schultz et al. Design and Synthesis of Semisynthetic Enzymes.
Köhrer et al. Specialized Components of the Translational Machinery for Unnatural Amino Acid Mutagenesis: tRNAs, Aminoacyl-tRNA Synthetases, and Ribosomes
Jaziri et al. Transliteration of a Short Genetic Message from Deoxyxylose (dXyloNA) to Deoxyribose (DNA) in Escherichia coli
Kowal Studies directed towards the development of an in vitro method for the site-specific incorporation of unnatural amino acids into proteins using unassigned codons in Micrococcus luteus
Tocchini-Valentini E. coli tRNA Leucine Identity and Recognition Sets